Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones

Journal of Medicinal Chemistry

Volumn 51, Issue 19, 2008, Pages 6230-6234

  Aponte, José C ^a   Verástegui, Manuela ^b   Málaga, Edith ^b   Zimic, Mirko ^b   Quiliano, Miguel ^b   Vaisberg, Abraham J ^b   Gilman, Robert H ^c   Hammond, Gerald B ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYL COMPOUND; CHALCONE DERIVATIVE; FLUOROURACIL; NIFURTIMOX;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI;

3T3 CELLS; ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; MYRISTICACEAE; PARASITIC SENSITIVITY TESTS; PLANT EXTRACTS; PLANTS, MEDICINAL; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOSOMA CRUZI;

EID: 53549092794     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800812k     Document Type: Article

References (28)

1. Nowakowska, Z. A review of anti-infective and anti-inflammatory chalcones. Eur. J. Med. Chem. 2007, 42, 125-137.
2. Boumendjel, A.; Boccard, J.; Carrupt, P.-A.; Nicolle, E.; Blanc, M.; Geze, A.; Choisnard, L.; Wouessidjewe, D.; Matera, E.-L.; Dumontet, C. Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure-Activity Relationship. J. Med. Chem. 2008, 51, 2307-2310.
3. Cabrera, M.; Simoens, M.; Falchi, G.; Lavaggi, M. L.; Piro, O. E.; Castellano, E. E.; Vidal, A.; Azqueta, A.; Monge, A.; Lopez de Cerain, A.; Sagrera, G.; Seoane, G.; Cerecetto, H.; Gonzalez, M. Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure-activity relationships. Bioorg. Med. Chem. 2007, 15, 3356-3367.
4. Sabzevari, O.; Galati, G.; Moridani, M. Y.; Siraki, A.; O'Brien, P. J. Molecular cytotoxic mechanisms of anticancer hydroxychalcones. Chem. Biol. Interact. 2004, 148, 57-67.
5. Rao, Y. K.; Fang, S.-H.; Tzeng, Y.-M. Differential effects of synthesized 2′-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution. Bioorg. Med. Chem. 2004, 12, 2679-2686.
6. Liu, M.; Wilairat, P.; Croft, S. L.; Tan, A. L.-C.; Go, M.-L. Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg. Med. Chem. 2003, 11, 2729-2738.
7. Lunardi, F.; Guzela, M.; Rodriguez, A. T.; Correa, R.; Eger-Mangrich, I.; Steindel, M.; Grisard, E. C.; Assreuy, J.; Calixto, J. B.; Santos, A. R. S. Trypanocidal and leishmanicidal properties of substitution-containing chalcones. Antimicrob. Agents Chemother. 2003, 47, 1449-1451.
8. Nwaka, S.; Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discovery 2006, 5, 941-955.
9. Buckner, F. S.; Verlinde, C. L.; La Flamme, A. C.; Van Boris, W. C. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. 1996, 40, 3245-3250.
10. El-Sayed, N.; Myler, P. J.; Bartholomeu, D. C.; Nilsson, D.; Aggarwal, G.; Tran, A.-N.; Ghedin, E.; Worthey, E. A.; Delcher, A.; Blandin, G.; Westenberger, S.; Caler, E.; Cerqueira, G. C. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005, 309, 409-415.
11. Du, X.; Hansell, E.; Doyle, P. S.; Caffrey, C. R.; Holler, T. P.; McKerrow, J. H.; Cohen, F. E. Synthesis and structure--activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. 2002, 45, 2695-2707.
12. Urbina, J. A.; Docampo, R. Specific Chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2003, 19, 495-501.
13. Vieira, N. C.; Espindola, L. S.; Santana, J. M.; Veras, M. L.; Pessoa, O. D. L.; Pinheiro, S. M.; Mendonca de Araujo, R.; Lima, M. A. S.; Silveira, E. R. Trypanocidal activity of a new pterocarpan and other secondary metabolites of plants from northeastern Brazil flora. Bioorg. Med. Chem. 2008, 16, 1676-1682.
14. Chibale, K.; Musonda, C. The Synthesis of Parasitic Cysteine Protease and Trypanothione Reductase Inhibitors. Curr. Med. Chem. 2003, 10, 1863-1889.
15. Aponte, J. C.; Estevez, Y.; Gilman, R. H.; Lewis, W. H.; Rojas, R.; Sauvain, M.; Vaisberg, A. J.; Hammond, G. B. Antiinfective and cytotoxic compounds present in Blepharodon nitidum (Asclepiadaceae). Planta Med. 2008, 74, 407-410.
16. Aponte, J. C.; Vaisberg, A. J.; Rojas, R.; Caviedes, L.; Lewis, W. L.; Lamas, G.; Sarasara, C.; Gilman, R. H.; Hammond, G. B. Isolation of cytotoxic metabolites from targeted Peruvian Amazonian medicinal plants. J. Nat. Prod. 2008, 71, 102-105.
17. Kavvadias, D.; Sand, P.; Youdim, K. A.; Qaiser, M. Z.; Rice-Evans, C.; Baur, R.; Sigel, E.; Rausch, W.-D.; Riederer, P.; Schreier, P. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br. J. Pharmacol. 2004, 142, 811-820.
18. Xu, B.; Pelish, H.; Kirchhausen, T.; Hammond, G. B. Large scale synthesis of the Cdc42 inhibitor secramine A and its inhibition of cell spreading. Org. Biomol. Chem. 2006, 4, 4149-4157.
19. Vutukuri, D. R.; Bharathi, P.; Yu, Z.; Rajasekaran, K.; Tran, M.-H.; Thayumanavan, S. A mild deprotection strategy for allyl-protecting groups and its implications in sequence specific dendrimer synthesis. J. Org. Chem. 2003, 68, 1146-1149.
20. Smith, A. B.; Rivero, R. A.; Hale, K. J.; Vaccaro, H. A. Phyllanthoside-phyllanthostatin synthetic studies. 8. Total synthesis of (+)-phyllanthoside. Development of the Mitsunobu glycosyl ester protocol. J. Am. Chem. Soc. 1991, 113, 2092-2112.
21. Chen, M.; Zhai, L.; Christensen, S. B.; Theander, T. G.; Kharazmi, A. Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother. 2001, 45, 2023-2029.
22. Buckner, F. S.; Verlinde, C. L. M. J.; La Flamme, A. C.; Van Voorhis, W. C. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob. Agents Chemother. 1996, 40, 2592-2597.
23. Vega, C.; Rolon, M.; Martinez-Fernandez, A. R.; Escario, J. A.; Gomez-Barrio, A. A. New pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase. Parasitol. Res. 2005, 95, 296-298.
24. Buckner, F. S.; Wilson, A. J.; Van Voorhis, W. C. Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for β-galactosidase. Infect. Immun. 1999, 67, 403-409.
25. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3717.
26. Zhao, Y.; Abraham, M. H.; Lee, J.; Hersey, A.; Luscombe, N. C.; Beck, G.; Sherborne, B.; Cooper, I. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res. 2002, 19, 1446-1457.
27. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
28. MolinspirationCheminformatics, Bratislava, Slovak Republic, http://www.molinspiration.com/services/properties.html. Accessed on June 16, 2008.